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Abstract 
Background: Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, 
yet its role in the pathophysiology of HF is not well‑defined. We sought to determine the consequences of HF neuro‑
hormonal activation in iron homeostasis and mitochondrial function in cardiac cells.
Methods: HF was induced in C57BL/6 mice by using isoproterenol osmotic pumps and embryonic rat heart‑derived 
H9c2 cells were subsequently challenged with Angiotensin II and/or Norepinephrine. The expression of several genes 
and proteins related to intracellular iron metabolism were assessed by Real time‑PCR and immunoblotting, respec‑
tively. The intracellular iron levels were also determined. Mitochondrial function was analyzed by studying the mito‑
chondrial membrane potential, the accumulation of radical oxygen species (ROS) and the adenosine triphosphate 
(ATP) production.
Results: Hearts from isoproterenol‑stimulated mice showed a decreased in both mRNA and protein levels of iron 
regulatory proteins, transferrin receptor 1, ferroportin 1 and hepcidin compared to control mice. Furthermore, mitofer‑
rin 2 and mitochondrial ferritin were also downregulated in the hearts from HF mice. Similar data regarding these key 
iron regulatory molecules were found in the H9c2 cells challenged with neurohormonal stimuli. Accordingly, a deple‑
tion of intracellular iron levels was found in the stimulated cells compared to non‑stimulated cells, as well as in the 
hearts from the isoproterenol‑induced HF mice. Finally, neurohormonal activation impaired mitochondrial function as 
indicated by the accumulation of ROS, the impaired mitochondrial membrane potential and the decrease in the ATP 
levels in the cardiac cells.
Conclusions: HF characteristic neurohormonal activation induced changes in the regulation of key molecules 
involved in iron homeostasis, reduced intracellular iron levels and impaired mitochondrial function. The current results 
suggest that iron could be involved in the pathophysiology of HF.
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Background
Heart failure (HF) is a devastating condition and repre-
sents a challenge for public healthcare systems [1]. The 
current understanding of its pathophysiology is based on 
the “neurohormonal hypothesis”, which states that HF 
progression is promoted by the long-term maladaptive 
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and deleterious effects of sustained neurohormonal 
activation in the heart and in rest of the cardiovascular 
system [2, 3]. Many of classical neurohormones such as 
norepinephrine (Nor) and angiotensin II (Ang II) are 
known to be synthesized directly within the myocardium 
and, therefore, act in an autocrine or paracrine manner 
[3, 4]. In fact, the sustained activation of these pathways 
lead to an increased plasma Ang II, epinephrine and Nor 
levels [5, 6]. The inhibition of these neurohormonal sys-
tems has demonstrated a consistent reduction in morbid-
ity and mortality in patients with systolic HF and is the 
basis of modern pharmacological treatment [7, 8].
However, these effective therapies have failed to pro-
mote a complete remission of symptoms and restore 
life expectancy in many patients. This has motivated an 
increasing interest in emerging therapeutic targets. In 
this regard, iron deficiency (ID) is present in up to 50% 
of HF patients [9, 10] and is associated with a higher risk 
of mortality and hospitalization [10, 11], reduced func-
tional capacity, and impaired health-related quality of life 
[12], independent of the presence of anemia [10, 12, 13]. 
Interestingly, intravenous iron supplementation has been 
recommended by European Society of Cardiology (ESC) 
HF guidelines as a potential therapeutic approach, since 
the correction of ID with intravenous iron alleviates HF 
symptoms, reduces risk of hospitalization and improves 
quality of life [14–16].
Although ID has been mainly considered as an extra-
cardiac co-morbidity complicating the course of HF, 
recent data suggest that it may actually interact directly 
with the mechanisms involved in HF initiation and pro-
gression [17–20]. Previous studies from our group sug-
gested an association between HF neurohormonal 
activation and systemic ID [17]. It has been shown that 
in chronic HF patients, the increase in the sympathetic 
activity (measured by Nor systemic levels) was associ-
ated with ID, independently of anemia [17]. In addition, 
Maeder et  al. suggested that the sympathetic activation 
found in HF patients may contribute to iron depletion, 
specifically in heart, since Nor stimulation may reduce 
the intracellular iron levels in cardiac cells by downreg-
ulating the transferrin receptor 1 (Tfr1) expression [18]. 
Other studies have shown that iron content in myocardial 
was reduced by 20–30% in patients with advanced HF 
[21]. Apart from its role in oxygen transport, iron plays 
an important role in cellular metabolism, impacting on 
the regulation of oxidative stress and ATP synthesis, as 
an enzymatic cofactor in the mitochondria [19, 22]. Radi-
cal oxygen species (ROS) directly impacts on the mito-
chondrial  Ca2+ homeostasis contributing to an altered 
contractibility and increasing the cardiac wall stiffness 
[23]. Hence, iron homeostasis is crucial for cells with 
high energy demand, such as cardiomyocytes [10, 19].
In spite of all the accumulating data, the interplay of 
iron in the pathophysiology of HF is not well-defined. We 
hypothesized that neurohormonal activation could be 
involved in the generation of ID in cardiac cells, directly 
impacting on the mitochondria function. Therefore, the 
aim of this study was to analyze the relationship between 
neurohormonal stimuli and iron homeostasis, as well as 
their role regulating the mitochondrial function in car-
diac cells.
Results
We designed a two-step experimental approach. First, the 
effect of HF over several molecules involved in iron regu-
lation was evaluated in hearts from a well-established 
isoproterenol-induced HF mice [24]. Second, the mecha-
nisms linking iron regulation, energy metabolism and 
mitochondrial function, were further explored in depth 
in heart-derived cell cultures H9c2 exposed to the neuro-
hormonal activation typically found in HF.
Changes in the gene expression and protein levels of iron 
regulatory molecules in the heart of isoproterenol‑induced 
HF mice
First, we analyzed the cardiomyocyte area on histological 
sections from mice hearts (Fig. 1a). As it is shown in the 
Fig. 1, isoproterenol induced cellular hypertrophy, com-
pared to control animals (Fig. 1a, b).
Both, the mRNA and protein levels of the main mol-
ecules related to cellular iron uptake, release and stor-
age, were analyzed in HF and control mice. First, it was 
determined the two iron regulatory proteins (Irp1 and 
Fig. 1 Isoproterenol induces cardiac hypertrophy. a Masson’s 
Trichrome staining of sections from ventricular myocardial of control 
(Ct) and isoproterenol (Iso) stimulated mice. b Quantification of 
cardiomyocytes area. Data were expressed as mean ± SEM (n = 8 per 
group) (***p < 0.001 vs control)
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2), which regulate the translation of several proteins 
involved in iron metabolism [21]. Irp1 (Fig.  2a) and 2 
(Fig.  2b) were down-regulated in mice stimulated with 
isoproterenol compared to control animals. Next, the lev-
els of the main iron transporters into the cell, Tfr1 and 
divalent metal transporter 1 (Dmt1), were also deter-
mined. Whereas Dmt1 was unaltered (Fig. 2c), Tfr1 was 
reduced in the hearts of HF mice (Fig. 2d).
In order to look deeper into the role of the molecules 
related to the cellular iron release, ferroportin 1 (Fpn1) 
(Fig.  3a), and its inhibitor, hepcidin antimicrobial pep-
tide (Hamp) (Fig.  3b) were analyzed. In the isoprotere-
nol-stimulated mice, the levels of both molecules were 
down-regulated when compared to control animals. 
Finally, the cytoplasmic iron storage molecule ferri-
tin, encoded by ferritin heavy chain 1 (Fth1) and ferri-
tin light chain 1 (Ftl1), was analyzed. No changes were 
found between the experimental groups in the Fth1 and 
Ftl1 mRNA (Fig. 3c), neither in the Ferritin protein lev-
els (Fig. 3d).
Regulation of mitochondrial iron metabolism molecules 
in the heart of HF mice
Due to the role of iron in mitochondrial function, the 
mitochondrial iron uptake transporters Mitoferrin 1 
(Mfrn1) (Fig. 4a) and 2 (Mfrn2) (Fig. 4b), and the mito-
chondrial iron storage molecule Mitochondrial ferri-
tin (Ftmt) (Fig.  4c) were analyzed. Whereas the Mfnr1 
was not modified, the Mfrn2 was down-regulated in the 
hearts from the HF animals. In addition, Ftmt was also 
down-regulated in hearts from isoproterenol-stimulated 
mice.
Intracellular iron depletion in the heart 
of isoproterenol‑induced HF mice
Finally, the total heart iron (Fig.  5a), as well as the iron 
ions  Fe2+ (Fig.  5b) and  Fe3+ (Fig.  5c), were analyzed in 
mice. As it is shown in Fig. 5, the iron ions were reduced 
in the hearts from the animals stimulated with isoproter-
enol compared to control ones.
Neurohormonal stimulation induced hypertrophy in H9c2 
cells
To further explore the role of neurohormonal activation 
in iron metabolism at cellular level, an in vitro cardiac 
cell model was studied. Since myocardial hypertrophy is 
a hallmark of HF [3], some of the classical markers of 
cardiac hypertrophy (Bnp and Myh7) [25] were assessed 
in the H9c2 cells stimulated with the neurohormonal 
stimuli (Ang II and/or Nor). As it is shown in Fig.  6, 
both Ang II and Nor induced an increase in the mRNA 
levels of Bnp and Myh7 (Fig.  6a). Similar results were 
found when the MYH7 protein levels were analyzed 
(Fig. 6b).
Neurohormonal activation induced changes 
in the intracellular iron metabolism molecules in H9c2 cells
The same molecules studied in mice were subsequently 
assessed in the in vitro neurohormonal activation model. 
Irp1 and 2 were significantly reduced when cells were 
exposed to all the experimental conditions (Fig. 7a, b). In 
addition, Tfr1 and Dmt1 were down-regulated in the set-
ting of any of the neurohormonal challenges (Fig. 8a, b).
With respect to cellular iron release, whereas Fpn1 
mRNA levels were reduced under Ang II or Nor treat-
ment alone, there were no changes in its expression 
when cells were simultaneously treated with both stimuli 
(Fig. 9a, left). Fpn1 protein levels did not change in any 
experimental condition (Fig. 9b, left). On the other hand, 
while Hamp was induced by Ang II treatment, its levels 
were reduced under the influence of Nor and simulta-
neous treatment with Nor and Ang II (Fig. 9a, right and 
Fig. 9b right).
Finally, although the stimulation with Nor produced a 
slight reduction in the Fth1 expression, there were no sig-
nificant changes when exposing cardiac cells to Ang II or 
both stimuli at the same time (Fig.  10a, right). Also, no 
significant changes in Ftl1 expression were found in any 
experimental condition (Fig.  10a, left). Accordingly, no 
significant changes were found in the cytoplasmic Ferri-
tin protein levels (Fig. 10b).
Neurohormonal activation depleted intracellular iron 
in H9c2 cells
Beyond the effects of neurohormonal activation on the 
molecules involved in iron metabolism, its effect on the 
intracellular iron levels was assessed in H9c2 cells. As it 
is shown in Fig. 11, the total iron (Fig. 11a), as well as the 
iron ions  Fe2+ (Fig. 11b) and  Fe3+ (Fig. 11c), were reduced 
in the cells challenged with Nor, Ang II, or their combi-
nation, when compared to control cells.
Neurohormonal activation promoted down‑regulation 
of Ftmt levels in H9c2 cells
The exposure to Nor and/or Ang II did not induce 
changes in the levels of the mitochondrial iron trans-
porters Mfrn1 and Mfrn2 (Fig. 12a, b). Interestingly, the 
mRNA and protein levels of the Ftmt were reduced in all 
the experimental conditions (Fig. 12c, d).
Page 4 of 18Tajes et al. Cell Biosci           (2021) 11:89 
Fig. 2 Isoproterenol‑induced HF mice heart presents changes in iron regulatory molecules. Analysis of (a) Irp1 mRNA and protein levels; b Irp2 
mRNA and protein levels; c Dmt1 mRNA and protein levels; and d Tfr1 mRNA and protein levels. Representative Western Blot image of all the 
analyzed proteins. Data were normalized by the Gapdh mRNA or protein levels and expressed as mean ± SEM (n = 7 per group for mRNA; n = 5 per 
group for protein); (*p < 0.05 and ** p < 0.01 vs control)
Page 5 of 18Tajes et al. Cell Biosci           (2021) 11:89  
Fig. 3 Isoproterenol‑induced HF mice heart presents changes in release and storage iron regulatory molecules. Analysis of (a) Fpn1 mRNA and 
protein levels, b Hamp mRNA and protein levels; c Fth1 and Ftl1 mRNA levels; and d Ferritin protein levels. Representative Western Blot image of all 
the analyzed proteins. Data were normalized by the Gapdh mRNA or protein levels and expressed as mean ± SEM (n = 7 per group for mRNA; n = 5 
per group for protein); (*p < 0.05 and **p < 0.01 vs control)
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Neurohormonal activation impaired mitochondrial 
function in H9c2 cells
Several parameters were assessed to characterize mito-
chondrial function in the neurohormonal activation 
in  vitro model. In the stimulated cells, the mitochon-
drial membrane potential was reduced (Fig. 13a). Addi-
tionally, there was an increase in the ROS production 
(Fig.  13b), along with a decrease in the ATP levels 
(Fig. 13c), regardless of the type of stimuli.
Discussion
ID has been associated with adverse outcomes in HF 
[26, 27]. Despite the clinical association between HF 
and ID, it is currently unknown whether intracellular 
Fig. 4 Isoproterenol‑induced HF mice myocardial tissue presents changes in mitochondrial iron regulatory molecules. Analysis of (a) Mfrn1 mRNA 
and protein levels, b Mfrn2 mRNA and protein levels, c Ftmt mRNA levels and protein levels. Representative Western Blot image of all the analyzed 
proteins. Data were normalized by the Gapdh mRNA protein levels and expressed as mean ± SEM (n = 7 per group for mRNA; n = 5 per group for 
protein); (*p < 0.05 and *** p < 0.001 vs control)
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ID in HF-cardiac cells is a consequence of the disease 
or, otherwise, directly takes part in the cellular altera-
tions leading the pathology. In the present study we 
demonstrated that neurohormonal activation related 
to HF promoted significant abnormalities in the iron 
metabolism regulatory systems, reduced intracellular 
iron levels and impaired mitochondrial function in car-
diac cells.
Although the unequivocal benefits of intravenous iron 
may be related to a peripheral effect [14, 28], recent stud-
ies support a cardiac-centered hypothesis. First, ferric 
carboxymaltose administration was associated with car-
diac iron repletion in cardiac magnetic resonance T2* 
and T1 mapping sequences [29]. Second, Doppler and 
strain rate echocardiography parameters were signifi-
cantly improved after intravenous iron administration 
in patients with stable systolic HF and ID without ane-
mia [30]. Third, recent data in patients with HF have 
correlated ID and reduced peak exercise capacity with 
impaired myocardial contractile reserve [31].
We set up a study with both in  vivo and in  vitro 
approaches. First, we used a well-established HF mice 
model induced by isoproterenol (β-adrenoceptor ago-
nist) osmotic pumps [24, 32]. Interestingly, these animals 
showed an increase of Ang II in blood and heart [33], 
thereby being a good model to study the effect of neuro-
hormonal activation. Moreover, the results found in the 
in vivo model were validated in H9c2 cardiac cells chal-
lenged with AngII, Nor or both, in order to mimic the 
neurohormonal activation with more than just on stimuli 
[3, 6].
To validate the neurohormonal activation cell model, 
we analyzed the expression of cardiac hypertrophy mol-
ecules (Bnp and Myh7) as hallmarks of HF [3, 34]. Our 
neurohormonal activation in  vitro model induced both 
mRNA and protein levels of cardiac hypertrophy markers 
in all the experimental conditions. Nevertheless, no syn-
ergistic effect was observed in cells stimulated with both 
stimuli simultaneously, possibly because the stimulation 
with each of them separately already achieved the maxi-
mum effect. Similarly, isoproterenol also induced cardio-
myocyte hypertrophy in mice.
Our data showed that the neurohormonal activation 
was related to a reduction of the intracellular iron lev-
els (both  Fe2+ and  Fe3+), thereby suggesting that neuro-
hormonal stimuli may contribute to cardiac alteration 
through intracellular ID. Interestingly, previous stud-
ies reported iron depletion in myocardial tissue of HF 
patients [18, 22] and highlighted the relevance of neuro-
hormonal activation leading to iron depletion.
At a cardiac cell level, ID may be due to several mecha-
nisms involving iron uptake, release and storage. Interest-
ingly, Irps are able to regulate the translation of different 
molecules related to these processes depending on iron 
levels [35]. As a matter of fact, Haddad et al. showed that 
Irps are crucial to maintain the iron supply in cardiomyo-
cytes and to prevent HF in mice [21]. Furthermore, the 
same study showed a decrease in the Irp activity from HF 
Fig. 5 Iron content depletion in the myocardial tissue of 
isoproterenol‑induced HF mice. Analysis of intracellular iron levels 
in hearts: (a) total iron content, b  Fe2+ ion content and c  Fe3+ ion 
content. Data were normalized by protein levels and expressed as 
mean ± SEM (n = 5 per group); (**p < 0.01 vs control)
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patients, related to a depletion of iron in the heart [21]. 
Accordingly, our study evidenced a down-regulation of 
the Irps in both of our experimental models. Next, we 
assessed the levels of Tfr1, which is involved in the tran-
ferrin-bound iron intake [36]. Xu et  al. showed that the 
lack of Tfr1 in knock-out mice produced a lethal cardio-
myopathy by diminishing the intracellular iron content 
and impairing mitochondrial function [37]. Besides, the 
levels of Tfr1 were found reduced in the myocardial tis-
sue of HF patients [18, 21]. Interestingly, Maeder et  al. 
demonstrated that cardiomyocytes treated with aldoster-
one or Nor showed a decrease in the Tfr1 levels [18]. In 
line with these studies, we found that Tfr1 was decreased 
in both hearts of HF mice and in the cardiac cells, in the 
setting of any of the neurohormonal challenges. Finally, 
although the Dmt1, related to the non-transferrin bound 
iron uptake [38], was slightly down-regulated in the neu-
rohormonal-stimulated cells, we found no modifications 
in hearts from isoproterenol-induced HF mice. As Kobak 
et al. recently reviewed, Dmt1 uptake could act as a com-
pensatory mechanism of the Tfr1-mediated iron import 
[39].
Neurohormonal stimuli also regulate the molecules 
involved in the cellular iron release, Fpn1 and Hamp. In 
the heart, Hamp participates in the local iron homeo-
stasis regulation by inhibiting Fpn1 function [40]. Fpn1 
exports intracellular iron outside the cell [41]. Deregu-
lations that affect the homeostasis of the Fpn1/Hepci-
din axis are known to produce iron overload or anemia, 
depending on the direction of the functional changes 
[42]. In the studied models we found different behav-
iors when analyzing these components. Whereas Fpn1 
mRNA levels were reduced under AngII and Nor stim-
ulation, the combination of both stimuli not induces 
changes in the expression of this gene in cardiac cells. 
In contrast, in the isoproterenol treated mice, we 
Fig. 6 Neurohormonal activation induces hypertrophy in H9c2 cells. Analysis of (a) Myh7 and Bnp mRNA levels. b Western blot showing MYH7 
protein levels. Data were normalized by the Gapdh mRNA (a) or protein (b) levels and expressed as mean ± SEM (n = 7 per group); (*p < 0.05, 
**p < 0.01 and *** p < 0.001 vs control)
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observed a decreased of Fpn1 compared to the control 
mice. On the other hand, Hamp was downregulated 
in isoproterenol-stimulated mice, as well as in cells 
challenged with Nor and both stimuli together. There-
fore, although the Fpn1 levels decrease in the HF mice 
model, probably as an attempt to stop the iron release, 
the reduced Hamp levels could favor the release of 
iron by Fpn1. Nevertheless, Hamp was upregulated in 
the cells challenged only with Ang II. Interestingly, the 
expression of Hamp is up-regulated in iron-deprived 
environments to secure the intracellular iron content 
by exerting a negative feed-back on Fpn1 in the car-
diomyocytes [40]. Our data suggest that while Ang II-
stimulated cells would try to retain the intracellular 
Fig. 7 Neurohormonal activation modifies iron metabolism related molecules in H9c2 cells. Analysis of (a) Irp1 (left) and Irp2 (right) mRNA levels 
and (b) IRP1 (left) and IRP2 (right) protein levels. Representative Western Blot image of all the analyzed proteins. Data were normalized by the Gapdh 
mRNA (a) or protein (b) levels and expressed as mean ± SEM (n = 7 per group); (*p < 0.05, **p < 0.01 and *** p < 0.001 vs control)
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iron by increasing the levels of Hamp, the exposure to 
a more intense neurohormonal insult would counteract 
this compensatory mechanism, and could favored the 
iron release. To note, the Hamp knock-out mice induce 
myocardial ID and dilated cardiomyopathy due to an 
increase of iron release [42].
On the other hand, our study did not evidence 
changes in the cytoplasmic iron storage molecule fer-
ritin by the neurohormonal activation stimuli (in any 
experimental condition). It is worth to note that ferritin 
may be further regulated by mechanisms others than 
Irps, such as oxidative stress [43].
Fig. 8 Neurohormonal activation modifies iron uptake molecules in H9c2 cells. Analysis of (a) Tfr1 (left) and Dmt1 (right) mRNA levels; b TFR1 (left) 
and DMT1 (right) protein levels. Representative Western Blot image of all the analyzed proteins. Data were normalized by the Gapdh mRNA (a) or 
protein (b) levels and expressed as mean ± SEM (n = 7 per group); (*p < 0.05, **p < 0.01 and ***p < 0.001 vs control)
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Altogether, our results suggest that neurohormonal 
activation may contribute to intracellular iron depletion 
by both increasing intracellular iron release and reduc-
ing extracellular iron uptake in cardiac cells. It means 
that the neurohormonal activation observed in HF 
patients could participate in disease progression through 
intracellular iron deprivation. However, further stud-
ies should be conducted to show the exact mechanisms 
underlying the neurohormonal regulation of these com-
ponents in the failing heart.
The role of iron in cardiac function is closely related 
to the mitochondria because of its role as an enzymatic 
Fig. 9 Neurohormonal activation modifies iron released molecules in H9c2 cells. Analysis of (a) Fpn1 (left) and Hamp (right) mRNA levels; (b) FPN1 
(left) and HAMP (right) protein levels. Representative Western Blot image of all the analyzed proteins. Data were normalized by the Gapdh mRNA (a) 
or protein (b) levels and expressed as mean ± SEM (n = 7 per group); (*p < 0.05, **p < 0.01 and ***p < 0.001 vs control)
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cofactor, and the role of mitochondrial dysfunction in 
HF is being increasingly recognized [44, 45]. Due to 
the importance of mitochondria in cardiomyocytes, 
we assessed the levels of the mitochondrial iron uptake 
transporter Mfrn and the iron storage molecule Ftmt. 
Mfrn1 and Mfrn2 were not altered in the neurohormo-
nal-stimulated cells, although in hearts from isopro-
terenol-induced mice the Mfrn2 was down-regulated. 
Paradkar et  al. showed that the reduction in Mfrn1 and 
Mfrn2 by RNA interference resulted in a decreased mito-
chondrial iron accumulation, heme synthesis and iron-
sulfur cluster synthesis [46]. Interestingly, Mfrn2 is more 
ubiquitously expressed than Mfrn1. Besides, we observed 
a down-regulation of the Ftmt levels in all the experimen-
tal conditions. Our data are in line with those reported 
in hearts from  Ftmt−/− mice, since these animals showed 
mitochondrial damage and fibril disorganization [40]. 
Moreover, given the antioxidant role of Ftmt [47], neu-
rohormonal activation may directly contribute to make 
cardiac cells more sensitive to oxidative stress. This 
hypothesis is further supported by other studies showing 
the decrease of antioxidant enzymes in hearts from HF 
patients [22].
Our data revealed that neurohormonal activation 
increased ROS production and reduced mitochondrial 
membrane potential in cardiac cells, showing impairment 
in the mitochondria. Mitochondria are crucial to main-
tain the high-energy demand of the heart [10, 22]. Actu-
ally, mitochondrial function has been found impaired 
in myocardial tissue of advanced HF patients [10]. The 
role of myocardial and cardiomyocyte iron depletion 
leading to mitochondrial malfunction has been high-
lighted as one of the drivers impairing contractile func-
tion [19]. Accordingly, mitochondrial dysfunction found 
in the cells challenged with the neurohormonal stimuli 
was related to a decrease in the ATP levels. Altogether, 
our results are in line with the data reviewed by Brown 
Fig. 10 Neurohormonal activation does not modify ferritin in H9c2 cells. Analysis of (a) Ftl1 (left) and Fth1 (right) mRNA levels; (b) Ferritin protein 
levels. Representative Western Blot image of all the analyzed proteins. Data were normalized by the Gapdh mRNA (a) or protein (b) levels and 
expressed as mean ± SEM (n = 7 per group); (*p < 0.05 vs control)
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et al. suggesting that mitochondrial impairment could be 
linked to cardiomyocyte injury and HF progression [45].
Finally, Fig.  14 summarized the key results obtained 
in this work, showing the effect of neurohormonal acti-
vation over the main iron metabolism molecules, the 
intracellular iron deficiency and the mitochondrial dys-
function at cardiac cell level (Fig. 14).
Conclusions
In conclusion, our data provide evidences that the neu-
rohormonal activation observed in the setting of HF pro-
motes a reduction in intracellular iron levels within cardiac 
cells and hampers mitochondrial function. The molecu-
lar mechanisms mediating this relationship may involve a 
transcriptional regulation of several iron metabolism genes 
in the cell. The current results suggest that ID could be a 
key element in the pathophysiological sequence that leads 
to the progression of HF. Nevertheless, further research is 




Sixteen 10-week-old male C57BL/6 mice received a con-
tinuous infusion of isoproterenol (ISO group; n = 8) or 
vehicle (saline) (Control group; n = 8) at a rate of 30 mg/kg/
day for 28 days using a subcutaneously implanted osmotic 
mini-pump (Alzet, model 1004), to generate a validated 
model of experimental HF in mice [24]. The animals were 
anesthetized by isoflurane inhalation during the implan-
tation pump. Buprenorphine (0.3 mg/kg, i.p.) was admin-
istered 10 min before surgery and after 24 h. Mice were 
euthanized by an i.p. injection of pentobarbital sodium 
(100 mg/kg). The experimental protocol was approved 
by the local Institutional Ethics Committee of the Institut 
Municipal d’Investigacions Mèdiques-Universitat Pompeu 
Fabra (CEEA-PRBB 16-1814I) and all animal procedures 
performed according to the guidelines from Directive 
2010/63/EU of the European Parliament on the protection 
of animals used for scientific purposes.
Heart samples were fixed in buffered 4% paraformalde-
hyde, embedded in paraffin and cut into 4 µm-thick slices. 
Heart sections were deparaffinized and rehydrated with 
xylene, etanol (100%, 90%, 70%) and water, and stained 
with Masson’s Trichrome Stain Kit (Polyscience) to assess 
cardiomyocyte hypertrophy. Representative ventricular 
photomicrographs (5–10 per animal) were acquired at 400 
× magnification with a light microscope (BX61, Olympus) 
and a mounted digital camera (DP72, Olympus). LV cardi-
omyocyte area was measured in at least 30 random cardio-
myocytes by outlining round to cuboidal-shaped nucleated 
cardiomyocites using the ImageJ software.
Cell culture model
Embryonic rat heart-derived cells (H9c2 cells) were main-
tained in a high-glucose Dulbecco’s modified Eagle’s 
medium (4.5 g/l glucose) (DMEM; supplemented with 
10% fetal bovine serum, 100 U/ml penicillin and 100 μg/
Fig. 11 Neurohormonal activation depletes intracellular iron in 
H9c2 cells. Analysis of intracellular iron levels: (a) total iron content, 
b  Fe2+ ion content and (c)  Fe3+ ion content. Data were normalized 
by protein levels and expressed as mean ± SEM (n = 7 per group); 
(*p < 0.05 and **p < 0.01 vs Control)
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ml streptomycin) at 37 °C and 5%  CO2. Cells were seeded 
in multi-well plates and serum deprived in DMEM sup-
plemented with 1% fetal bovine serum, 100 U/ml penicillin 
and 100 μg/ml streptomycin for 16 h, and then stimulated 
with 1 µM of Ang II (Sigma Aldrich, Spain) or/and 2 µM 
of Nor (Sigma Aldrich, Spain) for 48 (n = 7 in each experi-
mental group).
RNA preparation and quantitative real time reverse 
transcription‑polymerase chain reaction (RT‑PCR) analysis
Briefly, levels of mRNA were assessed by RT-PCR. Total 
RNA was isolated from H9c2 cells and mice heart using 
Nucleospin RNA II kit (Macherey–Nagel, Spain). RNA 
was quantified by a NanoDrop 1000 Spectrophotom-
eter (Thermo Scientific, Spain). TaqMan gene expression 
assays-on-demand (Thermo Scientific, Spain) were used 
for rat myosin heavy chain 7 (Myh7) (Rn00691731_m1), 
rat natriuretic peptide B (Bnp) (Rn00580641_m1), rat iron 
regulatory protein 1 (Irp1) (Rn00569045_m1) and mouse 
Irp1 (Mm01223514_m1), rat iron regulatory protein 2 
(Irp2) (Rn00575852_m1) and mouse Irp2 (Mm01179595_
m1), rat ferroportin (Fpn1) (Rn00591187_m1) and mouse 
Fpn1 (Mm01254822_m1), rat hepcidin antimicrobial 
peptide (Hamp) (Rn00584987_m1) and mouse Hamp 
(Mm00519025_m1), rat transferrin receptor 1(Tfr1) 
(Rn01474701_m1) and mouse Tfr1 (Mm01344485_m1), 
rat divalent metal transporter 1 (Dmt1) (Rn01533109_
m1) and mouse Dmt1 (Mm01308330_s1), rat ferri-
tin heavy chain 1 (Fth1) (Rn00820640_g1) and mouse 
Fth1 (Mm00850707_g1), rat ferritin light chain 1 (Ftl1) 
(Rn04341729_g1) and mouse Ftl1 (Mm03030144_g1), 
rat mitochondrial ferritin (Ftmt) (Rn01492073_s1) and 
mouse Ftmt (Mm01268428_s1), rat mitoferrin 1 (Mfrn1) 
(Rn01753423_m1) and mouse Mfrn1 (Mm00471133_
m1), rat mitoferrin 2 (Mfrn2) (Rn01411393_m1) and 
mouse Mfrn2 (Mm01199497_m1). Glyceraldehyde-
3-phosphate dehydrogenase (Gapdh) was used as the 
endogenous control, rat (Rn01775763_g1) and mouse 
(Mm99999915_g1). The results were normalized to 
Gadph, and relative quantification was performed using 
the comparative Ct (2-DDCt) method. mRNA levels were 
expressed as fold induction over control.
Immunoblotting
Whole protein extracts were collected from H9c2 cells 
in RIPA buffer (0.1% SDS, 150 mM NaCl, 1% Nonidet 
P40, 50 mM Tris–HCl, 0.5% deoxycholate) containing 
phosphatase and protease inhibitors (Roche Diagnos-
tics; Basel, Switzerland) and western blot analyses were 
performed using antibodies against MYH7, TFR1, FT, 
HAMP, FTMT and GAPDH from Abcam (USA), and 
FPN1, IRP1, IRP2, MFRN1, MFRN2 and DMT1 from 
Thermo Scientific (Spain). Detection was performed 
using the appropriate horseradish peroxidase (HRP)-con-
jugated secondary antibody (Dako; Glostrup, Denmark). 
The bands were visualized using ClarityTM Western 
ECL Substrate (BioRad, Spain) with the Quantity One 
software (BioRad, Spain). Differences in the protein lev-
els were expressed as arbitrary units (A.U.) percentage 
induction over control.
Intracellular iron determination
The intracellular iron ions content was determined in 
hearts and H9c2 cells using the colorimetric Iron Assay 
kit (Abcam, Spain), following the manufacturer’s instruc-
tions. All assays were performed in duplicate, and 
measured on a Tecan Infinite F200 microplate reader. 
Levels of total iron, as well as the ions  Fe2+ and  Fe3+, 
were expressed relative to untreated controls.
Mitochondrial membrane potential
The mitochondrial membrane potential was determined 
using the reagent TMRE-Mitochondrial Membrane 
Potential Assay Kit (Abcam; Spain). All assays were per-
formed in duplicate, and measured on a Tecan Infinite 
F200 microplate reader. Levels of fluorescence were 
expressed relative to untreated controls.
Intracellular radical oxygen species (ROS) determination
Intracellular ROS levels were determined using Cellular 
Reactive Oxygen Species Detection Assay Kit (Abcam; 
Spain). All assays were performed in duplicate, and meas-
ured on a Tecan Infinite F200 microplate reader. Levels of 
ROS were expressed relative to untreated controls.
Detection of adenosine triphosphate (ATP) content
Intracellular ATP content was determined by the ATP 
Assay kit (Abcam; Spain). All assays were performed in 
duplicate, and measured on a Tecan Infinite F200 micro-
plate reader. Levels of ATP were expressed relative to 
untreated controls.
Fig. 12 Neurohormonal activation modifies mitochondrial iron storage related molecules in H9c2 cells. Analysis of (a) Mfrn1 and Mfrn2 mRNA 
levels, (b) MFRN1 and MFRN2 protein levels, (c) Ftmt mRNA levels and (d) FTMT protein levels. Representative Western Blot image of all the analyzed 
proteins. Data were normalized by the Gapdh mRNA (a, c) or protein (b, d) levels and expressed as mean ± SEM (n = 7 per group); (*p < 0.05 and 
**p < 0.01 vs Control)
(See figure on next page.)
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Statistical analysis
Data are expressed as the mean ± standard error of the 
mean (SEM). Significant differences were established 
using Student’s t-test or one-way analysis of variance 
(ANOVA), followed by Bonferroni’s post hoc test, as 
appropriate. Data were analysed by using the GraphPad 
Instat programme (GraphPad Prism 6.01 Software Inc., 
USA). Differences were considered statistically signifi-
cant at P-value < 0.05.
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